ReviewMarine drugs2023
Secondary Metabolites from Marine-Derived Bacteria with Antibiotic and Antibiofilm Activities against Drug-Resistant Pathogens.
Review in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Marine Microbes: A Source of Novel Antibiotics against Antimicrobial-resistant (AMR) Pathogens: A Systematic Review.Current drug targets · 2026Pooled it
- Antibiofilm Activity and Chemical Profiling of Marine Bacterial Extracts with Antifouling Potential.Applied biochemistry and biotechnology · 2026Article
- Discovery of natural products that modulate signaling in patient-derived cells.RSC chemical biology · 2026Article
- Review
- Anticancer Potential of Piericidin A1 and Derivatives Isolated From Streptomyces sp. Associated With Palythoa variabilis From Brazilian Reefs.Chemistry & biodiversity · 2026Article
- From Polyphenols to β-Lactamases: Multitarget Strategies to Defeat Severe Resistance.International journal of molecular sciences · 2026Review
- Microbial Blue Bioprospecting: Exploring the Advances of Compounds Post-Discovery.Marine drugs · 2025Review
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Efficacy of ultraviolet-light emitting diodes in bacterial inactivation and DNA damage via sensitivity evaluation using multiple wavelengths and bacterial strains.Archives of microbiology · 2025Article
- Antimycobacterial activity of intertidal sediment-derived bacteria from False Bay, South Africa.Frontiers in microbiology · 2025Article
- Isolation and identification of antifungal, antibacterial and nematocide agents from marine bacillus gottheilii MSB1.BMC biotechnology · 2024Article
- Unlocking marine microbial treasures: new PBP2a-targeted antibiotics elicited by metals and enhanced by RSM-driven transcriptomics and chemoinformatics.Microbial cell factories · 2024Article
- A Novel Bacitracin-like Peptide from Mangrove-IsolatedAntibiotics (Basel, Switzerland) · 2024Article
- Recent Advances in Marine-Derived Compounds as Potent Antibacterial and Antifungal Agents: A Comprehensive Review.Marine drugs · 2024Review
- Review
- MariClus: Your One-Stop Platform for Information on Marine Natural Products, Their Gene Clusters and Producing Organisms.Marine drugs · 2023Article
- Cyclic Peptides in Pipeline: What Future for These Great Molecules?Pharmaceuticals (Basel, Switzerland) · 2023Review
- Dissolved Carbon Dioxide: The Lifespan ofBiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The search for new antibiotics against drug-resistant microbes has been expanded to marine bacteria. Marine bacteria have been proven to be a prolific source of a myriad of novel compounds with potential biological activities. Therefore, this review highlights novel and bioactive compounds from marine bacteria reported during the period of January 2016 to December 2021. Published articles containing novel marine bacterial secondary metabolites that are active against drug-resistant pathogens were collected. Previously described compounds (prior to January 2016) are not included in this review. Unreported compounds during this period that exhibited activity against pathogenic microbes were discussed and compared in order to find the cue of the structure-bioactivity relationship. The results showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.